Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Core Insights - Perspective Therapeutics, Inc. announced updated interim results from its Phase 1/2a clinical trial of [Pb]VMT-α-NET for treating unresectable or metastatic neuroendocrine tumors (NETs) at the ESMO Congress 2025 [1][2] Clinical Trial Results - The interim results were based on a data cut-off date of September 12, 2025, involving 55 patients across three dose cohorts who received at least one treatment of VMT-α-NET [2] - The objective response rate was reported at 44% (7 of 16 patients) in Cohort 2, with a median follow-up of 41 weeks, and 14 out of 16 patients remained free from progression [5][6] - Safety findings indicated no dose-limiting toxicities, no treatment-related discontinuations, and no serious renal complications among the patients [6] Expert Commentary - Richard Wahl, a professor at Washington University, highlighted the durable anti-tumor activity and excellent tolerability of [Pb]VMT-α-NET, emphasizing its potential as a treatment option for progressive NETs [4] - Markus Puhlmann, Chief Medical Officer, noted the compelling clinical profile of VMT-α-NET at the 5 mCi dose and the importance of the study for future registration [4] Future Developments - Initial efficacy data for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3 are expected to be presented in 2026 [5][9] - The company is exploring whether a higher dose or refined patient selection criteria could enhance VMT-α-NET's clinical profile [7] Financial Position - As of September 30, 2025, the company's cash, cash equivalents, and short-term investments were approximately $174.1 million, expected to fund operations into late 2026 [8]